|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7.
|
18252198 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
2,3,7,8-Tetrachlorodibenzo-p-dioxin modulates the induction of DNA strand breaks and poly(ADP-ribose) polymerase-1 activation by 17beta-estradiol in human breast carcinoma cells through alteration of CYP1A1 and CYP1B1 expression.
|
18558727 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tumors with p53 mutations are generally estrogen receptor negative and are associated with compromised distant disease free survival.
|
10699900 |
2000 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Breast tumors expressing estrogen receptor-alpha (ER) respond well to therapeutic strategies using selective ER modulators, such as tamoxifen.
|
16778215 |
2006 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Breast tumors lacking the estrogen receptor-alpha (ER-alpha) have increased incidence of resistance to therapy and poorer clinical prognosis.
|
18922159 |
2008 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Oestrogen receptor-alpha variant mRNA expression in primary human breast tumours and matched lymph node metastases.
|
10070900 |
1999 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Estrogen receptor (ER) expression and Her-2 amplification define specific subsets of breast tumors for which specific therapies exist.
|
12208864 |
2002 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
Estrogen receptor alpha (ERalpha) negative breast tumors often present with enhanced expression and/or activation of growth factor receptors, resulting in increased growth factor signaling and hyperactivation of MAPK (ERK1 and ERK2).
|
15056731 |
2004 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Estrogen receptor-alpha (ER-alpha) and -beta (ER-beta) play important roles in the carcinogenesis of breast tumors.
|
16033821 |
2005 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Oestrogen receptor alpha (ER alpha) is traditionally measured on all breast tumour specimens to identify those patients more likely to respond to anti-oestrogens.
|
17896177 |
2008 |
|
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
LHGDN |
Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
|
18485221 |
2008 |
|
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
|
18485221 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Estrogen receptor negative (ER(-ve)) and p53 mutant breast tumors are highly aggressive and have fewer treatment options.
|
22027149 |
2011 |
|
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Estrogen receptor gene methylation in human breast tumors.
|
2354445 |
1990 |
|
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
ESR1 methylation levels were also assayed in DNA from 155 invasive ductal carcinoma biopsies provided by the Breast Cancer Campaign Tissue Bank, and validated with DNA methylation profiles from the TCGA breast tumours (n = 356 ER-pos, n = 109 ER-neg).
|
25927974 |
2015 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Estrogen receptor alpha36 (ERalpha36), a variant of estrogen receptor alpha (ER) is expressed in about half of breast tumors, independently of the [ER+]/[ER-] status.
|
26080803 |
2015 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.
|
27542969 |
2016 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Estrogen receptor α (ERα) is expressed in approximately 70% of breast tumors, and considered as one of most effective targets in breast cancer therapy.
|
31518603 |
2019 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Estrogen receptor (ER)-beta mRNA splice variants have been identified in human breast tumors as well as normal human and mouse ovarian, uterine and mammary tissues.
|
9685228 |
1998 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A genetic model system with three mouse strains, one that develops ER-positive mammary tumors (p18 single deletion) and the others that develop ER-negative tumors (p16;Brca1 and p18;Brca1 compound deletion), human BRCA1 mutant breast cancer patient-derived xenografts, and human BRCA1-deficient and BRCA1-proficient breast cancer cells were used to determine the role of estrogen in activating epithelial-mesenchymal transition (EMT), stimulating cell proliferation, and promoting ER-negative mammary tumor initiation and metastasis.
|
29996906 |
2018 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A majority (~70%) of breast tumors are found to express estrogen receptor, and a significant portion (~90%) of ER-positive (ER<sup>+</sup>) breast tumors are also androgen receptor-positive (AR<sup>+</sup>).
|
29254284 |
2017 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives.
|
17562079 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A new approach, based on the competitive amplification of wild-type and exon-deleted estrogen receptor (ER) variant cDNAs, was used to screen 100 human breast tumors for the presence of ER variants.
|
8813116 |
1996 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.
|
17415682 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A previous study identified some patients with <i>GATA3</i> gene variants and breast cancer, suggesting that <i>GATA3</i> variants may contribute to tumorigenesis in estrogen receptor 1-positive breast tumors; however, these patients did not have HDR syndrome.
|
29593425 |
2018 |